AIFA Notes are the regulatory tool that defines the therapeutic indications for which a certain medicinal product can be charged to the National Health Service (NHS).
The Notes can be introduced in three cases:
- when a medicinal product is authorized for different clinical indications, of which only some are for relevant pathologies;
- when a medicinal product is aimed at preventing a risk that is significant only for one or more population groups;
- when a medicinal product is suitable not only for uses of documented efficacy, but also for improper uses.
In these cases, through the Notes, AIFA identifies, among all the indications for which a medicinal product is authorized, those to be charged to the NHS from a public health perspective, thus orienting therapeutic choices towards better efficacy and greater safety of use.
AIFA Notes therefore represent the regulatory tool aimed at guaranteeing an appropriate use of medicinal products, directing the prescribing activity of doctors on the basis of the evidence in the literature, without however interfering with the doctor's freedom of prescription.